title: Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study.
abstract: To assess the safety of an AS03-adjuvanted split virion H1N1 (2009) vaccine (Pandemrix) in persons vaccinated during the national pandemic influenza vaccination campaign in the UK.
  
  
  
  Prospective, cohort, observational, postauthorisation safety study.
  
  
  
  87 general practices forming part of the Medical Research Council General Practice Research Framework and widely distributed throughout England.
  
  
  
  A cohort of 9143 individuals aged 7 months to 97 years who received at least one dose of the AS03-adjuvanted H1N1 pandemic vaccine during the national pandemic influenza vaccination campaign in the UK was enrolled. 94% completed the 6-month follow-up. Exclusion criteria were previous vaccination with other H1N1 pandemic vaccine and any child in care.
  
  
  
  Medically attended adverse events (MAEs) occurring within 31 days after any dose, serious adverse events (SAEs) and adverse events of special interest (AESIs) following vaccination were collected for all participants. Solicited adverse events (AEs) were assessed in a subset of participants.
  
  
  
  MAEs were reported in 1219 participants and SAEs in 113 participants during the 31-day postvaccination period. The most frequently reported MAEs and SAEs were consistent with events expected to be reported during the winter season in this population: lower respiratory tract infections, asthma and pneumonia. The most commonly reported solicited AEs were irritability in young children aged <5 years (61.8%), muscle aches in children aged 5-17 years (61.9%) and adults (46.9%). 18 AESIs, experienced by 14 patients, met the criteria to be considered for the observed-to-expected analyses. AESIs above the expected number were neuritis (1 case within 31 days) and convulsions (8 cases within 181 days). There were 41 deaths during the 181-day period after vaccination, fewer than expected.
  
  
  
  Results indicate that the AS03-adjuvanted H1N1 pandemic vaccine showed a clinically acceptable reactogenicity and safety profile in all age and risk groups studied.
  
  
  
  ClinicalTrials.gov, NCT00996853.
authors: Department of Primary Care & Population Health,  University College London Medical School, London,  UK.
authors: Irwin
authors: I
authors: Nazareth
authors: Fernanda
authors: F
authors: Tavares
authors: Dominique
authors: D
authors: Rosillon
authors: François
authors: F
authors: Haguinet
authors: Vincent
authors: V
authors: Bauchau
references: Eur J Neurol. 2002 Jan;9(1):63-7
references: 11784378
references: JAMA. 1982 Aug 13;248(6):698-700
references: 7097920
references: Vaccine. 2010 Dec 16;29(2):266-73
references: 21034828
references: Lancet Neurol. 2005 Oct;4(10):627-34
references: 16168931
references: Vaccine. 2011 Nov 28;29(51):9467-72
references: 22019757
references: Vaccine. 2010 Feb 17;28(7):1740-5
references: 20034605
references: Br J Clin Pharmacol. 2012 May;73(5):801-11
references: 22082196
references: MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):400-2
references: 19390508
references: Vaccine. 2010 Aug 16;28(36):5837-44
references: 20600478
references: Am J Epidemiol. 2011 Aug 1;174(3):326-35
references: 21652600
references: MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):467-70
references: 19444150
references: Lancet Infect Dis. 2011 Feb;11(2):91-101
references: 21168369
references: MMWR Recomm Rep. 2009 Aug 28;58(RR-10):1-8
references: 19713882
references: MMWR Morb Mortal Wkly Rep. 2009 May 8;58(17):453-8
references: 19444146
references: Lancet. 2007 Aug 18;370(9587):580-9
references: 17707753
references: Vaccine. 2008 May 2;26(19):2378-88
references: 18407382
references: Vaccine. 2011 Aug 26;29(37):6358-65
references: 21596080
references: Arch Intern Med. 2006 Jun 26;166(12):1301-4
references: 16801513
references: BMJ Open. 2011 May 30;1(1):e000016
references: 22021725
references: Neurology. 1997 Feb;48(2):312-4
references: 9040712
references: BMJ. 2011 Jul 12;343:d3908
references: 21750072
references: MMWR Morb Mortal Wkly Rep. 2010 Jun 4;59(21):657-61
references: 20520590
references: J Neurol. 1995 Feb;242(3):143-6
references: 7751856
references: Ital J Neurol Sci. 1995 Apr;16(3):167-76
references: 7558771
references: Pediatr Infect Dis J. 2010 Jun;29(6):e35-46
references: 20375709
references: Clin Infect Dis. 2010 Sep 15;51(6):668-77
references: 20687838
references: J Neurol Sci. 2003 Dec 15;216(1):89-93
references: 14607307
references: Am J Epidemiol. 1979 Aug;110(2):105-23
references: 463869
references: N Engl J Med. 2001 Feb 1;344(5):319-26
references: 11172162
references: Mult Scler. 1997 Aug;3(4):243-7
references: 9372507
references: N Engl J Med. 1981 Jun 25;304(26):1557-61
references: 7231501
references: Influenza Other Respir Viruses. 2011 Sep;5(5):299-305
references: 21668694
references: Vaccine. 2011 Jun 10;29(26):4353-61
references: 21504774